07:00 , Sep 29, 2014 |  BioCentury  |  Finance

CureVac bet paying off

Although the Hopp family's biotech investments have posted mixed results in recent years, the €80 million marker Hopp put down in 2012 on CureVac GmbH seems to be paying off. The cancer vaccine and infectious...
07:00 , Sep 22, 2014 |  BC Week In Review  |  Company News

CureVac, Boehringer Ingelheim deal

CureVac granted Boehringer exclusive, worldwide rights to develop and commercialize CureVac's CV9202 . The vaccine is in a Phase Ib trial to treat metastatic non-small cell lung cancer (NSCLC). The deal includes a EUR35 million...
02:44 , Sep 19, 2014 |  BC Extra  |  Company News

Boehringer licenses CureVac's CV9202

Boehringer Ingelheim GmbH (Ingelheim, Germany) licensed exclusive, worldwide rights to develop and commercialize CV9202 from CureVac GmbH (Tuebingen, Germany). The candidate is in a Phase Ib trial to treat metastatic non-small cell lung cancer (NSCLC)....